Trump administration cuts funding for Illinois food assistance programs
According to the IDOA, the Local Food Purchase Assistance Program (LFPA) and the Resilient Food Systems Infrastructure Program (RFSI) would be shut down.
Funded through the American Rescue Plan, the LFPA reimbursed local governments for buying food from farmers and distributing it, via food pantries, at no cost.
More than 170 farmers have supplied food to 883 locations through the supported Illinois-EATS program.
The United States Department of Agriculture (USDA) approved $43 million for Illinois to fund the program for several years, starting in 2022, but the state is still missing $17.8 million, according to the IDOA.
The RFSI program provided grants to strengthen mid-supply chain infrastructure, like processing and distribution. Illinois received $5 million in 2024.
The IDOA said the USDA notified states that invoices would be processed only for costs incurred on or prior to January 19th, 2025.
'Cutting funds for these programs is a slap in the face to Illinois farmers and the communities they feed,' said Gov. JB Pritzker. 'The Trump Administration's refusal to release grant funds doesn't just hurt farmers in the program, it devastates our most vulnerable, food-insecure communities relying on meat, fresh produce and other nutritious donations.'
No reason was given for the cuts, but the Trump administration has made it a priority to reduce taxpayer spending within the federal government, utilizing recommendations from the Department of Government Efficiency (DOGE) to trim redundancy and waste.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
31 minutes ago
- New York Times
China's Biotech Is Cheaper and Faster
Just outside of Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and laboratories where global pharmaceutical companies can develop and manufacture drugs faster and cheaper than anywhere else. Amid the Trump administration's tariffs on China, I figured manufacturing hubs like this one would be wracked with anxiety. But when I visited Wuxi in April, government officials insisted that its research hub was flourishing. They were proud to tell me about their superstar labs and companies that are continuing to thrive. The fact that Chinese biotechnology stocks have surged over 60 percent since January seems to bolster this claim. The city's researchers certainly seemed positioned to be busy for decades. In its quest to dethrone American dominance in biotech, China isn't necessarily trying to beat America at its own game. While the U.S. biotech industry is known for incubating cutting-edge treatments and cures, China's approach to innovation is mostly focused on speeding up manufacturing and slashing costs. The idea isn't to advance, say, breakthroughs in the gene-editing technology CRISPR; it's to make the country's research, development, testing and production of drugs and medical products hyperefficient and cheaper. As a result, China's biotech sector can deliver drugs and other medical products to customers at much cheaper prices, including inexpensive generics. These may not be world-changing cures, but they are treatments that millions of people around the world rely on every day. And as China's reach expands, the world will soon have to reckon with a new leader in biotech and decide how it wants to respond. One such company that embodies the Chinese approach to biotech is Wuxi AppTec. It's a one-stop shop for pharmaceutical research and development, streamlining everything from early-stage drug discovery to young scientist recruitment and medication production. The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs. Though the Chinese government bargains hard with both foreign and domestic pharmaceutical companies to provide products at the right price in exchange for market access, the low prices that Chinese consumers pay are ultimately the result of Chinese biotech companies' ability to test and manufacture drugs at a pace far faster than their American counterparts. So far, American biotech giants don't seem to mind the competition, since their own use of companies like Wuxi AppTec allows them to dedicate more of their money to breakthrough research. Want all of The Times? Subscribe.
New York Post
an hour ago
- New York Post
Ukrainian sniper breaks world record with 13,000-foot kill shot against Russian forces: report
A Ukrainian sniper unit on Thursday reportedly broke the world record for the longest confirmed sniper kill, eliminating Russian troops from a distance of more than 13,000 feet. The shot, fired by a Ukrainian-produced rifle and aided by artificial intelligence and drone guidance, left two Russian soldiers dead in the area of Pokrovsk, Ukraine, the Kyiv Post reported. 'The record-breaking shot was made on Aug. 14, 2025, using artificial intelligence under the guidance of [an unmanned aerial vehicle] complex with a 14.5 mm alligator rifle,' said military journalist Yuri Butusov, according to the Kyiv Post. The shooting took place amid increased Russian attacks in the area surrounding Pokrovsk, which was once a city with more than 60,000 residents, the Post reported. The previous world record belonged to a 58-year-old Ukrainian sniper who eliminated a target from a distance of around 12,400 feet, the outlet added. The record-breaking shot reportedly took place a day before President Donald Trump's closely-watched summit Friday with Russian President Vladimir Putin. 3 A Ukrainian soldier in the sniper unit of the 108th Territorial Defense Brigade readies a rifle during training on Nov. 4, 2023. Anadolu via Getty Images 3 The previous world record was held by another Ukrainian sniper who took out a Russian soldier from nearly 2½ miles away with a high-tech rifle known as 'Horizon's Lord.' SBU 3 Ukrainian soldiers take part in a sniper shooting exercise at a training facility outside Kyiv on Nov. 21, 2023. AFP via Getty Images Putin, who spoke first in a joint press conference held by the two world leaders, described the talks as a 'constructive atmosphere of mutual respect.' Ukrainian President Volodymyr Zelensky is scheduled to meet with Trump in Washington, DC, Monday. Zelensky said in a post on X that he and Trump will 'discuss all of the details regarding ending the killing and the war.'
Business Insider
an hour ago
- Business Insider
What's Driving the Wild Swings in Tilray Stock (TLRY)?
Shares of Tilray Brands (TLRY) kicked off last week on a positive note after President Donald Trump said he is considering a proposal to reclassify marijuana as a less dangerous drug. Nonetheless, the stock ended the week with a 10.5% drop on Friday. Overall, TLRY stock has gained nearly 35% over the past five trading days, though it remains down more than 30% year-to-date. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. For context, Tilray Brands produces and distributes cannabis, hemp-based foods, and alcoholic beverages across multiple markets. What's Behind TLRY's Moves? Speaking to reporters in the White House briefing room, Trump said the review of marijuana's classification is in progress, and a decision could come within the next few weeks. He added that he hopes the decision 'will be the right one.' The proposed change would move marijuana to Schedule III, which is a category for drugs with accepted medical uses and lower abuse potential. Right now, U.S. law classifies cannabis as a Schedule I drug under the Controlled Substances Act, putting it in the same category as highly dangerous drugs like heroin. Nonetheless, the proposal is currently under review by the U.S. Drug Enforcement Administration (DEA). Separately, Tilray confirmed it is seeking an extension from Nasdaq to regain listing compliance. This disclosure has likely fueled volatility and contributed to the price reversal on Friday. What Does It Mean for TLRY? If marijuana is reclassified as less dangerous, it could lift TLRY stock by easing rules for cannabis companies in the U.S. Such a change would ease restrictions, expand medical and commercial opportunities, and attract more investors. Overall, TLRY stock has remained volatile in the past year. However, a move of this size is rare even for Tilray, suggesting the news had a major impact on how the market views the company. Is TLRY a Good Buy? TLRY stock based on two Buys and four Holds assigned in the past three months. Furthermore, the average Tilray stock price target of $0.94 per share implies a downside of over 10% from the current level.
